Fujifilm adding three 2,000L GE single-use bioreactors as part of $30m expansion

By Dan Stanton contact

- Last updated on GMT

GettyImages/Torsakarin
GettyImages/Torsakarin

Related tags: Investment, Biotechnology

Following a ‎¥14bn ($125m) investment in April, Fujifilm Corporation has committed a further ‎¥3.2bn across its biologics contract manufacturing business.

In April,​ Japan’s Fujifilm Corporation announced it was investing ‎¥14bn in its biologics contract development and manufacturing (CDMO) business to increase production capacity in the US and build an additional process development facility in the UK. And today the firm says it is investing a further ‎¥3.2bn ($30m) across the two sites.

Fujifilm Diosynth Biotechnologies’s monoclonal antibody (mAb) production facility in College Station, Texas will receive ¥2.2bn to bolster production, and will effectively double the planned bioreactor capacity expansion. The site was fully acquired from Kalon Therapeutics in March.

The firm’s site in Wilton, UK will receive ¥1bn to add a further 900m2​ of area at the 930m2​ mAb production development facility which opened its doors in September. Fujilfilm added the UK site and a facility in North Carolina in 2011​ from Merck & Co.

Spokesperson Kana Matsumoto told Biopharma-Reporter: “We invest capital investment in US and UK in order to incorporate the CDMO needs of monoclonal antibody that are growing particularly among growing biopharmaceuticals.”

“In order to respond to growing customer needs in this field, Fujifilm has decided to make additional investments earlier than scheduled.”

Matsumoto told us the firm’s current mammalian cell culture capacity is 9,000L, but is set to increase to 15,000L next year following the announced addition of three 2,000L single-use bioreactors in Texas in April.

This latest investment will add a further three 2,000L single-use systems, supplied according to Matsumoto by GE Healthcare, pushing total capacity to 21,000L across the three sites by 2019.

On the microbial front, current total fermentation tank capacity is 17,000L, not including 20,000L available through a collaboration at a plant owned by Merck & Co.​​

The continued expansions support ambitions to increase the CDMO’s biologics revenues to ¥100bn by 2023 – up from current sales of around ¥30bn – placing it in league with Lonza and Boehringer-Ingelheim.

Related news

Show more

Related products

show more

Rapid Biosafety Testing Enables the Future of Manufacturing

Rapid Biosafety Testing Enables the Future of Manufacturing

Viral Safety for mAb: Prevent, Detect, Remove | 23-Nov-2020 | Technical / White Paper

This white paper explores the factors driving the evolution toward faster biosafety testing and describes rapid approaches for adventitious agent testing...

Blazar™ Platform: Rodent Virus Panel

Blazar™ Platform: Rodent Virus Panel

Viral Safety for mAb: Prevent, Detect, Remove | 16-Nov-2020 | Technical / White Paper

We have a long history of developing innovative molecular technologies for cell line characterization and lot release testing for the biopharmaceutical...

Monitoring SARS-CoV-2 interaction with ACE2

Monitoring SARS-CoV-2 interaction with ACE2

Take the Right Path Upstream with MilliporeSigma | 02-Nov-2020 | Technical / White Paper

In this technical note, we investigate the interactions between the following: The spike glycoprotein binding with ACE2, Spike glycoprotein and anti-spike...

Related suppliers

Follow us

Products

View more

Webinars